Cytovance Biologics, a leading US-based contract development and manufacturing organization (CDMO) serving the biopharmaceutical industry, today announced the expansion of its upstream process ...

Many recombinant viral vectors for expression of ectopic antigens mimic a natural infection and can induce a robust immune response against certain pathogens and tumors. Host-restricted poxviruses and ...

Scaling a viral vector process from benchtop to clinical supply isn't a bigger version of monoclonal antibody (mAb) manufacturing, but an entirely different analytical challenge. Cell and gene therapy ...

Upstream titers of 3–5 g/L, and up to 10–13 g/L, are outpacing downstream capacity, creating chromatography, filtration, and UF/DF throughput bottlenecks that elevate cost and delay timelines. Complex ...